Health Check: Promedicus shares smash record $300 barrier on back of mega deals
Proteomics wins US reimbursement code for its diabetic kidney disease assay
Morgans says Neurizon shares are worth almost triple their current value
Shares in tearaway radiology imager ProMedicus (ASX:PME) this morning surged close to 10% after the company announced two new US customer contracts worth a total $190 million.
The first win is a $170 million, 10-year contract with UCHealth, for the company's suite of image viewing and storage tools.
The deal expands Promedicus into cardiology imaging, one of the adjacent 'ologies' the company has targeted.
UCHealth is a Colorado-based network of 14 hospitals, with affiliate clinics extending into Wyoming and Nebraska.
The second victory is a previously flagged renewal with the Louisiana-based Franciscan Missionaries of Our Lady Health.
This one has a minimum $20 million contract value over five years.
The deal renews a contract for the company's Visage 7 viewer, at a higher per-transaction fee. It also provides the merciful missionaries with Visage 7 Open Archive, which offers 'best-in-class interoperability'.
Promedicus CEO and co-founder Dr Sam Hupert says the deal shows there's a 'material opportunity' to upgrade Visage 7 to the bells-and-whistles open archive.
'Our pipeline remains strong and spans all market segments,' he chirps.
Silencing the naysayers
The latest deals should silence the Promedi-sceptics, who fear the $34 billion market cap stock is way overvalued.
In March, one fundie suggested the stock was being driven by 'confirmation bias': the notion that what's worked well in the past will continue to do so.
See also: Commonwealth Bank (ASX:CBA).
Indeed, Promedicus shares trade on an extravagant price-earnings (PE) multiple of 200 times. This is based on current year earnings estimates.
But the PE used to be more like 300 times. Evidently stronger profits – rather than a lower share price – caused the contraction.
In February Promedicus shares hit $298 before pulling back by more than 30%. This was amid the US climate of fear enveloping healthcare stocks.
Painchek is on a roll – and it doesn't hurt a bit
PainChek (ASX:PCK) reports strong uptake of its smartphone-based device for assessing pain when the patients – typically nursing home residents – are unable to do so.
The company says contracted annual recurring revenue grew by 10%, $5.4 million.
Net contracted licences (to nursing homes) increased 9% to 110,000, with no attrition.
Painchek dominates the local aged care market and has a decent share of the UK sector, which is one and a half times as big as Australia's.
Painchek has a dominant position in the local aged care market and a decent share of the UK sector, which is one and a half times bigger.
The company also has a presence in Canada and has been chatting to the US Food & Drug Administration (FDA) about the path to US approval.
Painchek also is eyeing the bigger pre-verbal kids' sector.
All up, Painchek has contracts with more than 1800 aged care facilities and had carried out more than 12 million digital pain assessments to date.
Today's disclosure was a sales update rather than the full June quarter, so it didn't get into the nitty-gritty of cash burn and such.
Proteomics wins US reimbursement code
If biotechs aren't getting reimbursed in the US they might as well pack their bags and go home – if Customs have let them in to Trumpland in the first place.
So, we duly report that Proteomics International Laboratories (ASX:PIQ) has won a Current Procedural Terminology (CPT) reimbursement code, as granted by the American Medical Association.
While a CPT code sounds, well, procedural, it's the standard lingua franca for public and private health insurance programs.
The CPT code is for Proteomics' predictive blood test for diabetic kidney disease, Promarker D.
In the meantime, the Centers for Medicare and Medicaid Services will release its pricing for the test in September.
Promarker D is a simplified, immunoassay-based diagnostic that predicts accurately kidney function decline in adults with type 2 diabetes.
Studies showed Promarker D predicted the disease onset in up to 86% of otherwise healthy diabetics.
Is this the breast partnership yet for Bcal?
Still on tests, BCAL Diagnostics (ASX:BDX) has struck a commercial partnership deal with Cancer Care Associates (CCA), one of Australia's biggest private oncology networks.
CCA will adopt Bcal's Breastest Plus, the company's non-invasive breast cancer diagnostic.
'Initially starting in Sydney, the collaboration is designed to accelerate the clinical uptake and validation with doctors,' the company says.
Designed as an adjunct to mammography, Breastest Plus analyses lipids in the blood. It's intended for use for women with dense breast tissue, who are at higher risk of breast cancer than their 'fatty' breasted brethren.
Bcal dubs the tie-up as a 'significant commercial milestone, establishing an additional pathway to market adoption and patient access through one of Australia's most prominent oncology networks'.
The company expects initial revenue in the current financial year, 'with expansion potential as clinical adoption grows".
Bcal launched Breastest Plus locally on March 27, generating first revenue for the company. We'll know more when the company releases its June quarter report later this month.
Morgans values Neurizon shares at a 160% premium
Broker Morgans says Neurizon Therapeutics' (ASX:NUZ) deal with the maker of its repurposed drug candidate should save the company both time and money for little upfront cost.
Neurizon yesterday said it had entered into an exclusive global licensing agreement with Elanco Animal Health.
This enables Neurizon to access key data pertaining to monepantel, which had been approved as a sheep drench.
Monepantel is the active ingredient in Neurizon's human drug candidate NUZ-101, to treat amyotrophic lateral sclerosis, ALS. ALS is the most common form of motor neurone disease.
Morgans says the access to the clinical and non-clinical data should 'significantly truncate timelines' ahead of potential FDA approval.
The terms of the deal are 'heavily back ended', with a nominal upfront amount.
The company pays up to US$9.75 million in development milestones but most of the contingent amount – US$65 million – is based on sales.
'The time and risk saved is worth a small clip of the ticket and provides further incentive for Elanco to help Neurizon open doors to potential partners globally,' Morgans says.
While acknowledging the 'considerable clinical risk', Morgans reckons the stock is worth 42 cents compared with today's opening value of 16 cents.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
an hour ago
- ABC News
Flu cases, hospitalisations on the rise as SA government urges for more vaccinations
Reported flu cases across South Australia have spiked 70 per cent this year, according to government data, prompting fears about the health system's capacity to cope with more hospital presentations. The state government released data on Friday showing there had been 10,569 reported flu cases so far in 2025, up from 6,212 at the same time last year. It comes after a total of 1,627 new flu cases were reported in the past week, which is almost the highest number of cases reported in any week for the past five years, according to the government. The number of people hospitalised due to the flu has also increased to 1,042 this year, compared to 673 at this point last year. Health Minister Chris Picton said the flu case spike was causing two problems: an increase in hospital presentations and more health workers taking sick leave. "We have seen a spike in hospitalisations and significantly more hospitalisations because of the flu than the same time last year," Mr Picton said. "And also, we've seen more absences in terms of many of those workplaces because the workers themselves have the flu." Mr Picton said workplace flu absences were affecting GPs, doctors, and aged care workers. He said there had "never been a more important time to make sure that you're vaccinated for flu". "That's why we're focusing our efforts particularly in terms of young kids, but also older people and people who have chronic health conditions." South Australia's take-up of the flu vaccine is the highest of any mainland states at 32.1 per cent of the population, according to the state government. That is higher than Victoria at 29.9 per cent, New South Wales at 26.8 per cent and Western Australia and Queensland at 25.8 per cent, the government said. The flu spike comes as the state's hospital system continues to struggle with demand. Ambulance ramping hours soared to their third-highest level on record in May, with patients spending 4,791 hours waiting outside public hospitals for treatment. The data, the most recent released by the state government, was taken before the onset of winter and the spike in flu cases Last year's winter saw ambulance ramping reach record levels, with the paramedic's union fearing 2025 will be even worse. Paul Ekkelboom, general secretary of the Ambulance Employees Association (AEA), said the flu figures were "alarming". "History tells us it's only going to get worse from here," he said, adding it was "only a month into winter". "It's placing a huge strain on our health system, every winter there is an increase in the demand and this includes flu cases." Mr Ekkelboom said "from all accounts" ramping hours were going up, adding that ambulance crews were dealing with fatigue and burnout. "We are concerned it's only a matter of time before this situation, where demand can't be met, results in negative patient outcomes," he said.
ABC News
an hour ago
- ABC News
Donald Trump just won the fight to remake America in three big ways
Donald Trump's "big, beautiful bill" is an extraordinary piece of legislation that brings many of the US president's MAGA dreams to life. It blew up his bromance with his biggest billionaire backer and could end up costing him considerable political capital. But it means many of his most drastic domestic policies will now become the law of the land. It will change the US — and the world — in some ways that are obvious, and probably in others that are unforeseeable. Which of those ways matters most is open for debate. But there are three areas where we can be sure to see some things dramatically transform. America's been home to millions of undocumented migrants for decades. About 8 million are estimated to be in the US workforce, and industries like agriculture and construction have become dependent on them. Under some administrations, their presence has been unofficially tolerated. A lot of big cities granted them "sanctuary" protections to prevent their deportation. Some of these "illegal" workers are even given special "ITIN" numbers so they can file taxes. And in 2022 they paid an estimated $US97 billion ($147 billion). (It's worth noting more than a third of that money went to social welfare programs they couldn't access.) So the US has long been referred to as the "land of hope" for people from abroad seeking better lives. But the legislation delivers on Trump's promise to strip a lot of that hope away. The incentives to come here are being removed, and people here without legal status are being encouraged to self-deport or risk harsh consequences. (In what could become an interesting exception, Trump has been talking about lifelines for unauthorised migrants who work on farms, if the farmers vouch for them.) The bill will inject more than $US100 billion to hire enforcement agents, continue work on the Mexican border wall, and double the size of detention facilities. The bill also puts in place a bunch of new barriers for refugees or asylum seekers hoping to stay in the US. Immigrants who are found eligible for humanitarian protection will be hit with a $US1,000 fee to get it. Seeking asylum will yield bills of at least $US100. Applying for a work permit will cost $US550 at a minimum. Many Americans applaud these moves. The White House says the new fees will help support what's become an expensive system. And Trump's crackdown remains popular with many Americans after big spikes in unauthorised border crossings in the Biden era created a situation that many saw as unsustainable. For environmentalists, the final version of the bill isn't quite as bad as it could have been. They know Trump's no fan of renewable energy. Solar farms, he says, are "ugly as hell". And wind turbines have been "destroying the place". An earlier version of the bill reflected his disdain for renewables with a proposed new tax on solar and wind projects. That triggered forecasts of the demise of those industries, until a small group of Republican senators forced the tax's removal. But many experts still see the bill as another big retreat from the fight to contain climate change by the US, the world's second-largest producer of greenhouse gases (after China). While the proposed new tax is dead, so are clean energy tax credits — for renewable energy, electric vehicles and efficient homes — that were brought in by former president Joe Biden. The priority moves back to oil and gas. The bill will make it easier to lease public land for drilling and mining, and cut the royalties oil and gas producers pay the government. Multiple studies project the bill's implementation will cause greenhouse gas emissions to rocket in relation to what they would have been. Princeton University modelling projects the bill will increase US greenhouse gas emissions by 470 million tonnes per year by 2035 (compared to where they would have been without the bill). That's an increase of more greenhouse gas than Australia produces in a year in total. And that's before you factor in other measures Trump is implementing to wind back climate and clean-energy policies. Trump's oil-thirsty energy policy often boils down to a three-word slogan: "Drill, baby, drill." The bill will help power the drilling. Most credible independent analysis points to a widening of the vast gap between America's haves and have-nots as a result of the bill. Its centrepiece is what Trump heralds as the largest tax cut in American history. Many analysts point out the income tax cuts disproportionately favour the wealthy, but they've been in place since 2017, meaning people won't really notice a change. But making those cuts permanent will cost $US4.5 trillion over a decade. So, despite some of the spin to the contrary, that revenue loss will be partially covered by cuts to Medicaid — the government program that provides health insurance for low-income Americans. The White House frames this as a rooting out of waste and fraud, and a refocusing on providing services for the neediest Americans the program was designed for. Congress's budget office estimates about 12 million Americans will lose their health coverage, saving the government $US1 trillion. Millions of Americans are also expected to lose the help of the national food stamp program that helps keep poorer people fed. The Trump administration is sensitive to the criticism this bill unfairly benefits the rich. And there are measures that mean some people on the poorer end of the social spectrum may be better off. For example, workers in low-paying service jobs, who rely on tips to make a living, will appreciate that tips are now exempt from tax. There are also tax credits for seniors and parents — and if you're a fisherman or whaling captain in Alaska, there are tax benefits for you too, inserted into the bill to win over that state's holdout Republican senator. But overall, most experts say the socio-economic scales will tip further in the favour of richer Americans. For those with less, the US already lacks the welfare benefits of places like Australia, where things like Medicare and Centrelink are sometimes taken for granted. But the protections offered by America's few safety nets will now be rolled back further.
Daily Telegraph
4 hours ago
- Daily Telegraph
Jon Bon Jovi dragged into dispute over $65 million mansion
Jon Bon Jovi has been dragged into a property dispute after he reportedly refused to sell his $US43 million ($A65 million) mansion to a mysterious buyer who's snapping up properties in the sought-after area. According to the Wall Street Journal, an anonymous buyer has 'been quietly assembling one of the most valuable private estates' in Palm Beach — which sits mere minutes from President Donald Trump's Mar-a-Lago resort. So far, the unnamed buyer has forked out $US250 million ($A380 million) on four separate homes in the Florida enclave in recent months. The estate is said to include a $US178 million ($A271 million) piece of prime oceanfront land that was initially put on the market by cosmetics mogul William Lauder — who is heir to the Estée Lauder fortune — in 2023 for $US200 million ($A304 million), as well as two separate homes that sit across the street from that plot. Sources told the Journal the unidentified real estate mogul is far from done with the spending spree. The buyer is said to already have their sights set on another investment property: a Mediterranean-style mansion that sits alongside their newly acquired waterfront land. The home is owned by the 'Livin' on a Prayer' singer. MORE: Fresh blow for Perry amid split 'Let go': Common item Mariah refuses to own 'Never coming back': Depp reveals sad demise The acquisition of the rocker's dwelling would provide the buyer with one of the most sizeable waterfront properties in Palm Beach — made all the more impressive by the addition of the two properties that sit directly behind it. Yet, the apparent real estate scheme has reportedly hit a major snag with Bon Jovi, who is said to have 'resisted overtures to sell his property'. Property records seen by Realtor indicate the seven-bedroom, 12-bathroom home was last purchased in July 2020 for $US43 million ($A65 million) via an LLC — of which Bon Jovi's longtime business manager Charles Sussman was listed as the manager. The home had originally been listed for $US44.9 million ($A68.3 million) in January of that year and was described as a 'stunning direct oceanfront estate' complete with a workout room, a temperature-controlled wine cellar, private in-home elevators, and two oceanfront loggias, as well as a separate pool cabana. Bon Jovi's home sits directly to the left of the Lauder land that was reportedly purchased in February of this year in an off-market deal. Sources told the Journal the buyer paid close to the reduced asking price of $US178 million ($A271 million) for the plot. The land was originally purchased by Lauder in two separate deals. The first acre was bought up in 2020 for $US25.4 million ($A38.6 million), one year before the businessman added the second 1.8-acre property for an undisclosed sum. Initially, the two plots had been home to two separate oceanfront mansions, which Lauder demolished to make space for his own enormous dwelling. However, he shelved those plans and opted to put the vacant land on the market. In addition to that expansive plot, the anonymous buyer is said to have also picked up two dwellings that sit directly behind it, although neither dwelling ever came on the market. Property records show that one of those homes was owned by Thomas Harvey and his wife, Cathleen Black, who bought the dwelling for $US4.2 million ($A6.3 million) in 2018. Though Realtor estimates the home is now worth around double that, the Journal reports that the buyer paid a staggering $US18 million ($A27 million) for it. Mr Harvey told the outlet in an email that the person made an 'unsolicited offer' on his house — while adding that he does not know their identity. Days later, the dwelling next door to Mr Harvey's property was also sold, this time for $US30 million ($A45 million), according to the Palm Beach Daily News, having previously been registered to a trust. That home, which was also purchased in an off-market deal, had last traded hands for $US5.3 million ($A8.07 million) in 2017 and was last linked to an LLC. Both properties, per the Palm Beach Daily News, were most recently purchased via LLCs that are registered in Delaware: Creekshore LLC and Mango Leaf LLC. According to The Real Deal, discussions about the potential purchase of Bon Jovi's home are still ongoing, despite the singer's reluctance to part ways with his property. The buyer is also said to have begun conversations about buying the home that sits on the other side of the Lauder land. That home is currently owned by casino mogul William M. Rickman Jr., who purchased it in 2016 for $US13.1 million ($A19.9 million). Built in 1935, the property boasts six bedrooms and 6.5 bathrooms, as well as water frontage. Though the identity of the buyer has not yet been confirmed, sources have claimed to the Real Deal the person believed to be behind these multimillion-dollar deals is Microsoft mogul Charles Simonyi, who spent years working alongside Bill Gates. Gates' name was also thrown into the mix of potential buyers, along with former Microsoft CEO Steve Ballmer, suggesting the deals all have strong ties to the computer company. All three men boast incredibly impressive property portfolios, and each owns at least one dwelling in the popular Seattle enclave of Hunts Point, Washington State which is widely considered to be something of a haven for billionaire tech moguls. Parts of this story first appeared in Realtor and was republished with permission. MORE: 'Lonely': Who gets what in Holly, ex split 'Big allure': Secret MJ homes reveal sad life Wild reason Charles can't kick Andrew out
